Clinical Research Study| Volume 131, ISSUE 8, P945-955.e3, August 2018

Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program



      Data on gender differences in oral anticoagulation for stroke prevention in patients with atrial fibrillation are conflicting, largely limited to regional reports and vitamin K antagonist use. We aimed to analyze gender-specific anticoagulant prescription patterns early following the introduction of non–vitamin K antagonist oral anticoagulants (NOACs) in a large, global registry on atrial fibrillation.


      The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is an international registry program involving patients with newly diagnosed atrial fibrillation (<3 months from arrhythmia onset). We used data from 15,092 consecutive patients (median age, 71.0 years; 45.5% were women) enrolled between 2011 and 2014. Globally, 79.7% of women and 80.2% of men were anticoagulated; the absolute between-gender difference in prevalence of anticoagulant use was −0.5% (95% confidence interval, −1.8% to 0.8%). Vitamin K antagonists were prescribed to 32.8% and 31.9% (NOACs 46.8% and 48.3%) of women and men, respectively.


      No confounder for the association between gender and anticoagulant prescription was identified. Between-gender differences in anticoagulant use (lower use in women compared with men by decreasing order of magnitude of the difference) were found for CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category [female]) score = 1; CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke) score = 0; previous bleeding; age <65 years; no history of hypertension; myocardial infarction; coronary artery disease; North America region; and specialist office setting.


      Globally, the prevalence of anticoagulant use is similar in women and men. The decision to prescribe oral anticoagulation seems to depend predominantly on guideline-related differences in stroke risk stratification rather than on gender.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Benjamin E.J.
        • Wolf P.A.
        • D'Agostino R.B.
        • Silbershatz H.
        • Kannel W.B.
        • Levy D.
        Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.
        Circulation. 1998; 98: 946-952
        • Stewart S.
        • Hart C.L.
        • Hole D.J.
        • McMurray J.J.V.
        A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.
        Am J Med. 2002; 113: 359-364
        • Hart R.G.
        • Pearce L.A.
        • McBride R.
        • Rothbart R.M.
        • Asinger R.W.
        Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I III Clinical Trials.
        Stroke. 1999; 30: 1223-1229
        • Fang M.C.
        • Singer D.E.
        • Chang Y.
        • et al.
        Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and Risk factors in Atrial fibrillation (ATRIA) study.
        Circulation. 2005; 112: 1687-1691
        • Mikkelsen A.P.
        • Lindhardsen J.
        • Lip G.Y.H.
        • Gislason G.H.
        • Torp-Pedersen C.
        • Olesen J.B.
        Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study.
        J Thromb Haemost. 2012; 10: 1745-1751
        • Cheng E.Y.
        • Kong M.H.
        Gender differences of thromboembolic events in atrial fibrillation.
        Am J Cardiol. 2016; 117: 1021-1027
        • Cove C.L.
        • Albert C.M.
        • Andreotti F.
        • Badimon L.
        • Van Gelder I.C.
        • Hylek E.M.
        Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms.
        Thromb Haemost. 2014; 111: 385-391
        • Lip G.Y.H.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.G.M.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272
        • Camm A.J.
        • Kirchhof P.
        • Lip G.Y.H.
        • et al.
        Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
        Eur Heart J. 2010; 31: 2369-2429
        • Camm A.J.
        • Lip G.Y.H.
        • De Caterina R.
        • et al.
        2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association.
        Europace. 2012; 14: 1385-1413
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
      1. Atrial Fibrillation: The Management of Atrial Fibrillation—PubMed - NCBI.
        (Available at:)
        Date accessed: January 13, 2016
        • Ogawa S.
        • Aonuma K.
        • Tse H.F.
        • et al.
        The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation.
        J Arrhythmia. 2013; 29: 190-200
        • Humphries K.H.
        • Kerr C.R.
        • Connolly S.J.
        • et al.
        New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome.
        Circulation. 2001; 103: 2365-2370
        • Avgil Tsadok M.
        • Jackevicius C.A.
        • Rahme E.
        • Humphries K.H.
        • Behlouli H.
        • Pilote L.
        Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation.
        JAMA. 2012; 307: 1952-1958
        • Dagres N.
        • Nieuwlaat R.
        • Vardas P.E.
        • et al.
        Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation.
        J Am Coll Cardiol. 2007; 49: 572-577
        • Lip G.Y.H.
        • Laroche C.
        • Boriani G.
        • et al.
        Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation.
        Europace. 2015; 17: 24-31
        • Huisman M.V.
        • Lip G.Y.H.
        • Diener H.C.
        • et al.
        Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
        Am Heart J. 2014; 167: 329-334
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • De Vos C.B.
        • Crijns H.J.G.M.
        • Lip G.Y.H.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart survey.
        Chest. 2010; 138: 1093-1100
        • Wacholder S.
        Binomial regression in GLIM: estimating risk ratios and risk differences.
        Am J Epidemiol. 1986; 123: 174-184
        • Olesen J.B.
        • Lip G.Y.H.
        • Lindhardsen J.
        • et al.
        Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a “real world” nationwide cohort study.
        Thromb Haemost. 2011; 106: 739-749
        • Potpara T.S.
        • Lip G.Y.H.
        Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
        Prog Cardiovasc Dis. 2015; 58: 177-194
        • Camm A.J.
        • Pinto F.J.
        • Hankey G.J.
        • et al.
        Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.
        Europace. 2015; 17: 1007-1017
        • Nielsen P.B.
        • Larsen T.B.
        • Skjøth F.
        • Overvad T.F.
        • Lip G.Y.
        Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study.
        Sci Rep. 2016; 6: 27410
        • Thompson L.E.
        • Maddox T.M.
        • Lei L.
        • et al.
        Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: a report from the National Cardiovascular Data Registry (NCDR ®) PINNACLE Registry.
        J Am Heart Assoc. 2017; 6 (e005801)
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        Circulation. 2014; 130: e199-e267
        • Lip G.Y.H.
        • Skjøth F.
        • Rasmussen L.H.
        • Larsen T.B.
        Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
        J Am Coll Cardiol. 2015; 65: 1385-1394
        • Fauchier L.
        • Lecoq C.
        • Clementy N.
        • et al.
        Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley atrial fibrillation project.
        Chest. 2016; 149: 960-968
        • Chao T.F.
        • Liu C.J.
        • Wang K.L.
        • et al.
        Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc Score (Beyond Sex) receive oral anticoagulation?.
        J Am Coll Cardiol. 2015; 65: 635-642
        • Friberg L.
        • Skeppholm M.
        • Terént A.
        Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1.
        J Am Coll Cardiol. 2015; 65: 225-232
        • Verma A.
        • Cairns J.A.
        • Mitchell L.B.
        • et al.
        2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2014; 30: 1114-1130
        • Lip G.Y.H.
        • Nielsen P.B.
        • Skjøth F.
        • Rasmussen L.H.
        • Larsen T.B.
        Atrial fibrillation patients categorized as “Not for Anticoagulation” according to the 2014 Canadian Cardiovascular Society algorithm are not “Low Risk.
        Can J Cardiol. 2015; 31: 24-28
        • Nielsen P.B.
        • Skjøth F.
        • Overvad T.F.
        • Larsen T.B.
        • Lip G.Y.H.
        Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation.
        Circulation. 2018; 8: 832-840
        • Mazurek M.
        • Huisman M.V.
        • Rothman K.J.
        • et al.
        Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry.
        Thromb Haemost. 2017; 12: 2376-2388